Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load. The Japanese ...
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
Teva Pharmaceutical Industries Ltd. ADR-3.78% $21.4B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback